Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4410 NETest can predict the tumour burden in neuroendocrine tumours

Introduction: Neuroendocrine tumours (NETs) are rare malignancies characterised by slow growth and a lack of reliable biomarkers for predicting tumour burden, treatment response, and prognosis.

Conference:

Presenting Author:

Authors: You T, Zhou N, Tang H, Ying J, Wang C,

Keywords: NETest, biomarker, NET,

#3612 Cystatin C may serve as a suitable blood-based biomarker to monitor renal functional decline in patients scheduled for peptide receptor radionuclide therapy

Introduction: Peptide receptor radionuclide therapy (PRRT) for treating somatostatin receptor (SSTR)-positive tumors may be associated with nephrotoxicity.

Conference:

Presenting Author: Hasenauer N

Authors: Hasenauer N, Hartrampf P, Weich A, Higuchi T, Schirbel A,

Keywords: sstr, theragnostics, prrt, renal, nephrotoxicity,

#3274 hPG80 (Circulating Progastrin), a novel blood-based biomarker for detection of well-differentiated neuroendocrine tumors

Introduction: Current blood-based biomarkers for neuroendocrine tumors (NETs) lack both sensitivity and specificity. Human circulating progastrin (hPG80) is a novel biomarker for NETs and is easily measured in plasma using an ELISA test.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Chauhan A, Prieur A, Kolesar J, Arnold S, Cousin T,

Keywords: neuroendocrine tumor, progastrin, hPG80, blood-based biomarker,

#3202 Plasma cell-free DNA from metastatic gastroenteropancreatic neuroendocrine neoplasms contains tumor-associated copy number alterations

Introduction: Recently, tumor-derived molecular alterations were detected in cell-free DNA (cfDNA) from gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) patients. In-depth evaluation of the biomarker potential of cfDNA is warranted, as better blood-based biomarkers are needed for GEP-NENs.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Boons G, Vandamme T, Lybaert W, Roeyen G, Rondou T,

Keywords: cell-free DNA, shallow whole-genome sequencing, gastroenteropancreatic neuroendocrine neoplasm, biomarker,

#2220 Validation of a Blood-Based Biomarker Test for the Diagnosis and Management of Bronchopulmonary Neuroendocrine Tumors

Introduction: There is currently no effective blood biomarker for lung neuroendocrine neoplasia diagnosis and management.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Modlin I

Authors: Modlin I, Kidd M, Lewczuk-Myślińska A, Chung K, Ćwikła J,

Keywords: bronchopulmonary, lung, biomarker, PCR, diagnostics, progression,